Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Revenue (2020 - 2025)

Historic Revenue for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $4.3 million.

  • Evoke Pharma's Revenue rose 6140.46% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 6739.69%. This contributed to the annual value of $10.2 million for FY2024, which is 9784.11% up from last year.
  • Latest data reveals that Evoke Pharma reported Revenue of $4.3 million as of Q3 2025, which was up 6140.46% from $3.8 million recorded in Q2 2025.
  • Evoke Pharma's Revenue's 5-year high stood at $4.3 million during Q3 2025, with a 5-year trough of $90421.0 in Q1 2021.
  • In the last 5 years, Evoke Pharma's Revenue had a median value of $1.1 million in 2023 and averaged $1.6 million.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 822062.46% in 2021, then plummeted by 1057.01% in 2022.
  • Evoke Pharma's Revenue (Quarter) stood at $360571.0 in 2021, then skyrocketed by 120.86% to $796370.0 in 2022, then skyrocketed by 110.45% to $1.7 million in 2023, then skyrocketed by 97.4% to $3.3 million in 2024, then grew by 29.49% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $3.8 million for Q2 2025, and $3.1 million during Q1 2025.